FIELD: biotechnology.
SUBSTANCE: method for processing tumour cells with a composition containing sodium dichloroacetate (DCA) and caffeine sodium benzoate is proposed. The measurement of antitumour activity is based on the distribution of cells by DNA content, which confirms the apoptosis of tumour cells. The effectiveness of the combined effect is assessed by the level of cells with less DNA than the diploid set (sub-G1 population) that result from the fragmentation of the nuclei of apoptotic cells.
EFFECT: invention provides high antitumour activity and selectivity of sodium dichloroacetate while reducing toxic effects in non-tumourous cells.
8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARAMCEUTICAL COMPOSITION FOR TREATMENT OF ONCOLOGICAL DISEASES | 2012 |
|
RU2484814C1 |
| METHOD OF TUMOUR CELLS RADIOSENSITIZATION | 2019 |
|
RU2723393C1 |
| N,N'-HYDRAZINO-BIS-ISATIN DERIVATIVES WITH ANTITUMOR ACTIVITY | 2023 |
|
RU2796559C1 |
| COMPOSITION INHIBITING TUMOR GROWTH AND SURVIVAL RATE | 2019 |
|
RU2707554C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT GROWTHS | 2019 |
|
RU2710273C1 |
| PHARMACEUTICAL COMPOSITION FOR ONCOLOGICAL DISEASES | 2011 |
|
RU2463053C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT GROWTHS OF PROSTATE GLANDS | 2015 |
|
RU2589266C1 |
| AGENT HAVING SELECTIVE ACTION ON TUMOR CELLS, ACTIVATING APOPTOSIS THEREOF AND PREVENTING FORMATION OF RESISTANCE THEREOF | 2018 |
|
RU2694547C1 |
| AGENT FOR TARGETED THERAPY OF MALIGNANT GROWTHS | 2018 |
|
RU2699558C2 |
| METHOD OF TREATING MELANOMA IN VIVO | 2023 |
|
RU2824428C2 |
